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Pureredcellaplasia(PRCA)isararebonemarrowfailuresyndromedeﬁnedbyaprogressivenormocyticanaemiaandreticulocyto-
penia without leukocytopenia and thrombocytopenia. Secondary PRCA can be associated with various haematological disorders,
such as chronic lymphocytic leukaemia (CLL) or non-Hodgkin lymphoma (NHL). The aim of the present review is to investigate
the infrequent association between PRCA and lymphoproliferative disorders. PRCA might precede the appearance of lymphoma,
may present simultaneously with the lymphoid neoplastic disease, or might appear following the lymphomatic disorder. Possible
pathophysiological molecular mechanisms to explain the rare association between PRCA and lymphoproliferative disorders
are reported. Most cases of PRCA are presumed to be autoimmune mediated by antibodies against either erythroblasts or
erythropoietin, by T-cells secreting factors selectively inhibiting erythroid colonies in the bone marrow or by NK cells directly
lysing erythroblasts. Finally, focus is given to the therapeutical approach, as several treatment regimens have failed for PRCA.
Immunosuppressivetherapyand/orchemotherapyareeﬀectiveforimprovinganaemiainthemajorityofpatientswithlymphoma-
associated PRCA. Further investigation is required to deﬁne the pathophysiology of PRCA at a molecular level and to provide
convincing evidence why it might appear as a rare complication of lymphoproliferative disorders.
1.Introduction
Pureredcellaplasia(PRCA),initiallydescribedbyKaznelson
in 1922 [1], is a rare disorder, characterized by the presence
of a severe normochromic, most frequently normocytic
anaemia and reticulocytopenia (<1%) associated with a
marked reduction of the bone marrow erythroid precursors
(<5%) and normal production of the white blood cell and
megakaryocyticlineages[2–4].Therefore,itispresumedthat
the defectlies within the erythroid precursors and not within
the stem cells as seen in aplastic anaemia [2].
PRCA is a rare bone marrow failure disorder without
geographic or racial predilection. All ages can be aﬀected.
If present in children, it is called transient erythroblastope-
nia of childhood, an acute and self-limited disorder, which
might be diﬃcult to distinguish from congenital causes
of anaemia, such as Diamond-Blackfan anemia. Former
nosology included various terms like chronic hypoplastic
anaemia, pure red-cell agenesis, primary red-cell anaemia,
and erythrophthisis [2].
The classiﬁcation of PRCA involves (i) the congenital
disorders of PRCA, which usually manifest themselves early
in life, (ii) primary PRCA, which occurs in the absence
of any underlying disorder and is predominantly autoim-
mune in origin, despite the idiopathic cases, and (iii) the
acquired or secondary PRCA syndrome. The acquired form
of PRCA presents either as an acute self-limited disease,
mainly encountered in children, or as a chronic illness,
more commonly seen in adults. Thus, PRCA may present
as a primary haematological disorder in the absence of any2 The Scientiﬁc World Journal
other disease or secondary to parvovirus infection, collagen
vascular disease, leukaemia, lymphoma, other lymphopro-
liferative disorders, thymoma, solid tumors, treatment with
recombinant human erythropoietin or other drugs, ABO-
incompatible haematopoietic stem cell transplantation and
pregnancy (Table 1)[ 5] .T h ec o u r s ec a nb ea c u t ea n d
self-limiting or chronic with rare spontaneous remissions,
depending on the cause [6].
Since PRCA is a rare disorder, haematologists should be
alert to include PRCA in the diﬀerential diagnosis in cases
of severe normochromic and normocytic anaemia combined
with reticulocytopenia and normal production of the white
blood cell and megakaryocytic lineages. Clinicians often fail
to diagnose PRCA. The experience of our center includes
only few cases of PRCA during a period of twenty years,
involving only one published case of PRCA combined with
small lymphocytic lymphoma (SLL) [3].
Acquired forms of PRCA must be distinguished from
congenital forms of PRCA, such as Diamond-Blackfan anae-
mia, Fanconi anaemia, and congenital dyserythropoietic
anaemias. Acquired PRCA occurring in childhood (tran-
sient erythroblastopenia of childhood) may be diﬃcult to
distinguish from Diamond-Blackfan anaemia. A history
of normal blood counts, late onset of manifestation, and
transient disease course are characteristic of transient ery-
throblastopenia of childhood. Interestingly, a distinction
between myelodysplastic syndrome (MDS) with erythroid
hypoplasia and idiopathic PRCA might be more diﬃcult [2].
The aim of the present review is to investigate the infre-
quent association between PRCA and lymphoproliferative
disorders. Possible pathophysiological molecular mecha-
nisms to explain the infrequent association between PRCA
and lymphoproliferative disorders are provided, according
to the literature. Finally, focus is given to the therapeutical
approach, as several treatment regimens have failed for
PRCA.
2.PRCACasesAssociatedwith
Lymphoproliferative Disorders
As stated above, PRCA has rarely been reported in asso-
ciation with lymphoproliferative disorders, as one of the
autoimmune diseases seen during the course of lymphoid
malignancies. Nevertheless, the relationship between PRCA
andtheunderlyingdisordersremainstobeelucidated.PRCA
might precede the appearance of a lymphoproliferative dis-
order, may present simultaneously with the lymphoid neo-
plastic disease, or might appear following the lymphomatic
disorder, either in relapse or interestingly, even in remission
of it [7]. The Japanese Collaborative Study Group for PRCA
r e p o r t s8c a s e sw i t hl y m p h o m af r o mac o h o r to f1 8 5P R C A
patients in a period of time between 1990 and 2006 in Japan.
Hence, acquired PRCA, because of lymphoma, is infrequent,
as it involves approximately one new case every two years
in Japan [7]. A review of the literature in the same study
has provided 22 additional cases of lymphoproliferative
disorders-associated PRCA worldwide from 1978 to 2007
[7]. Various histologic subtypes of lymphoid malignancies
in association with PRCA, either of the B-cell type or of the
T-cell type, have been documented (Table 2)[ 3, 4, 7–14].
The prevalence of PRCA associated with lymphoproliferative
disordersmaybehigher,astheremightexistcaseswhichhave
not been published.
3.Pathophysiological Mechanisms
3.1. Evidence Favoring the Notion of B-Cell Participation in
the Pathogenesis of Secondary PRCA, Related to Lymphopro-
liferative Disorders. Early demonstrations of factors in the
patients’ sera that inhibit erythropoiesis in vivo and in vitro
led to the hypothesis that these inhibitors could be IgG
antibodies, either complement-binding, directly cytotoxic,
targeting erythroblasts in vitro, or inhibiting haemoglobin
synthesis [15]. These IgG antibodies might derive directly
from a possible B-cell clone or could be polyclonal [15].
The antigenic targets for autoantibodies have not been well
characterized, but various stages of erythroid diﬀerentiation
can be aﬀected, as seen in the reduction of erythroid burst-
forming units or erythroid colony-forming units. In certain
cases of antibody-mediated PRCA, the involvement of the
complement system is prerequisite to disease causation [2].
Some other cases of adult autoimmune PRCA might be
induced by antibodies produced following a viral or bacterial
infection that might cross-react with erythroid precursor
cells or erythropoietin [16].
In addition, a possible model for antibody-induced red
cell aplasia is the identiﬁcation of PRCA associated with
antierythropoietin antibodies in rare cases [2]. The possible
molecular mechanism of antibody-mediated reduction of
erythropoiesis includes direct complement-mediated lysis of
red-cellprogenitorsandtheformationofimmunecomplexes
with erythropoietin, which result in functional inactivation
and the removal of erythropoietin from the circulation [16].
An alternative notion involves obstruction of the erythropoi-
etin receptor or another red-cell signalling pathway by anti-
erythroblast antibodies [16].
3.2. Evidence Supporting the Idea of a T-Cell or NK-Cell
Implication in the Pathogenesis of Secondary PRCA, Related
to Lymphoproliferative Disorders. Initial ﬁndings suggesting
the implication of T cells, either polyclonal or monoclonal,
in the pathogenesis of PRCA, due to lymphoproliferative
disorders, resulted from the coexistence of thymoma and
PRCA, or T-LGL and PRCA [14]. Interestingly, PRCA is the
second most common haematologic disease found in T-LGL
patients, exceeded only by autoimmune hemolytic anaemia
[14]. The mechanism of erythroid inhibition may vary
and may include direct cytotoxic T-lymphocyte-mediated
attack of the erythroid precursors or production of soluble
inhibitory and proapoptotic cytokines by the cytotoxic T-
lymphocytic population that directly aﬀect the erythroid
series [2].
Interestingly, LGL expansion may be the disorder most
commonly associated with PRCA. These LGLs may be of
T-celltypeorofnaturalkiller(NK)-celltype.T-LGLsexpress
CD3 and a T-cell receptor (TCR) of αβ-o rγδ-type. On
the contrary, NK-LGLs are CD3 negative, thus they do not
expressaTCRatthecellsurface.Typically,theseNK-LGLsdoThe Scientiﬁc World Journal 3
Table 1: Classiﬁcation of PRCA [2, 5].
Congenital PRCA
Primary autoimmune PRCA
Primary idiopathic PRCA
Secondary (acquired) PRCA, due to thymoma
Secondary PRCA, because of haematological malignancies (CLL, T-LGL/NK-LGL leukaemia, myeloma, NHL, MDS, ALL)
Secondary PRCA, related to infections (parvovirus B19, EBV, HIV, CMV, viral hepatitis, leishmaniasis, staphylococcemia)
Acquired PRCA, due to ABO-incompatible haematopoietic stem cell transplantation
Acquired PRCA, related to pregnancy
Secondary PRCA, because of autoimmune diseases (Sj¨ ogren’s syndrome, SLE, RA, mixed connective tissue disease, autoimmune
hepatitis)
Secondary PRCA, because of previous treatment with recombinant human erythropoietin or other drugs (azathioprine, allopurinol,
penicillin, linezolid, estrogens, ticlopidine, lamivudine, ﬂudarabine)
Acquired PRCA, related to solid tumors (thyroid cancer, renal cell carcinoma)
Acquired PRCA, due to severe nutritional deﬁciencies
Table 2: Histologic subtypes oflymphoid malignancies inassociationwith PRCA[3,4, 7–14]. Literature review was performed in references
[4, 7, 11, 12] and the additional cases have been added to the Table.
Histologic subtype of lymphoproliferative disorder Number of Cases (61 Total) References
Diﬀuse large B-cell lymphoma (DLBCL) 8 Hirokawa et al., 6 cases, 2009 [7], Sung et al., 1 case,
2007 [8], Suzuki et al., 1 case, 2007 [9]
Hodgkin’s disease 4 Hirokawa et al., 4 cases, 2009 [7]
Small lymphocytic lymphoma (SLL) 1 Vlachaki et al., 1 case, 2008 [3]
B chronic lymphocytic leukaemia (B-CLL) 7 Castelli et al., 1 case, 2002 [10] Narra et al., 6 cases,
2006 [11]
Nodal marginal zone lymphoma (NMZL) 1 Hirokawa et al., 1 case, 2009 [7],
Splenic marginal zone lymphoma (SMZL) 3 Narra et al., 1 case, 2006 [11], Anastasiadis et al., 2
cases, 2009 [4]
Mycosis fungoides 1 Hirokawa et al., 1 case, 2009 [7]
Angioimmunoblastic T-cell lymphoma (AITL) 12 Hirokawa et al., 4 cases, 2009 [7], Choi et al., 8 cases,
2010 [12]
Follicular lymphoma (FL) 7 Hirokawa et al., 6 cases, 2009 [7], Kuramoto et al., 1
case, 1998 [13]
Precursor T-lymphoblastic lymphoma (T-LBL) 1 Hirokawa et al., 1 case, 2009 [7]
Adult T-cell leukaemia/lymphoma (ATLL) 1 Hirokawa et al., 1 case, 2009 [7]
T-cell large granular lymphocyte (T-LGL) leukaemia 15 Go et al., 15 cases, 2001 [14]
not rearrange the TCR genes α, β, γ,a n dδ. Clonal expansion
of T-LGLs of γδ-type has been described in PRCA cases,
combined with malignancy [17]. Hence, apart from the
direct CD8(+) cytotoxic T-lymphocytic mediated attack of
the erythroid precursors, related to major histocompatibility
complex I (MHC-I), there is a second mechanism of T-cell
toxicity, implicating a clonal expansion of T-LGLs, which
is independent of MHC-I-restricted CD8(+) cytotoxic T-
lymphocytes.
The malignant T-LGLs, in the latter mechanism, carry
killer cell inhibitory receptors (KIRs), which inhibit the lytic
machinery of the killer cell, when the target cell expresses
the HLA class I antigen to which the particular KIR binds
[17]. Tumor cells, frequently, lose HLA class I antigens
as an escape mechanism to avoid recognition by MHC-
I-restricted CD8(+) T-lymphocytes. Nevertheless, in this
case, they can be destroyed by cytotoxic MHC-unrestricted
killer cells (T-LGLs) expressing KIRs. Thus, when red-cell
progenitors progressively lose HLA class I antigens from
their surface, KIRs fail to deliver an “oﬀ” signal to the killer
T-LGLs, leading to red-cell destruction by T-LGLs [17]. In
the aforementioned condition, the activated killer T-LGLs,
via their TCR, recognize ligands on the red-cell progenitors,
thereby triggering red-cell destruction and causing PRCA.
These ligands/antigens have not been well described. LGL-
lymphokine secretion, causing red-cell lysis has also been
proposed. Hence, in addition to T-lymphocytes expressing
αβ- TCR, T cells with a γδ- TCR can mediate PRCA [2].
The myeloid cells express normal levels of HLA class I
molecules that bind to the KIRs on the T-LGLs and deliver
“oﬀ” signals to the killer cells. The same mechanisms exist
for NK-LGLs, with the diﬀerence that NK-LGLs do not4 The Scientiﬁc World Journal
express a TCR, but may be positively triggered by circulating
antibody against red-cell antigens, activating NK-receptors
and adhesion molecules [17].
Finally, an interesting theory has been reported. There
seems to be a balance between the various degrees of
expression of HLA class I alleles on the surface of possible
target cells. Thus, while one HLA class I allele may present an
antigenicpeptidetoT-LGLsforlysis,otherHLAclassIalleles
may at the same time inhibit cytolysis by binding to the KIRs
[18].
3.3. PRCA Pathogenesis: B Cell or T Cell or Both? Clonal
or Polyclonal? The question of whether a B-cell clone or a
T-cell clone participates in the pathogenesis of secondary
PRCA, due to malignant lymphomas or lymphoproliferative
disorders, is intriguing. Most cases of PRCA are presumed
to be autoimmune mediated by antibodies against either
erythroblasts or erythropoietin, by T-cells secreting factors
selectively inhibiting erythroid colonies in the bone marrow
or by natural killer (NK) cells directly lysing erythroblasts
[11]. The above-mentioned pathophysiological mechanisms
might coexist to the same patient. An example is the
concurrent presence of T-LGL and B-NHL or T-LGL and B-
CLL to patients diagnosed with PRCA [14].
An interesting mechanism has been reported concerning
antibodies against red-cell progenitors binding to CD16 on
the LGLs. Hence, cytotoxicity can be induced by antibody
cross-linking the TCR of the T-LGLs with the Fc receptor
on target cells or by antibody cross-linking the Fc receptor
on the T-LGLs or NK-LGLs (CD16) with any speciﬁc ligand
for the antibody on the target cells. Thus, T-LGLs (αβ-
TCR or γδ-TCR) may use the same mechanism of NK-
mediated lysis. Then, the TCR is not directly involved in
the recognition of red-cell progenitors. The latter involves
an interaction between antibodies (B cells) and T cells
(LGLs or NK-LGLs) for the pathogenesis of PRCA in lym-
phoproliferative disorders [19, 20]. The existing molecular
mechanisms, based on the literature, linking PRCA and
lymphoproliferative disorders are highlighted in Table 3.
Most T-LGL proliferations associated with PRCA are
probably clonal, even though polyclonal expansions of T-
LGLs, such as following an immune response against an
unknown antigen, may be linked to autoimmunity [19]. The
molecular demonstration of clonality in some LGL patients
might mean dominance of one or a few clones within a
polyclonal population of LGLs. Interestingly, many patients
with T-LGL expansions have a chronic course, and the
demonstration of clonality by itself does not obligatory
mean malignancy. Benign clonal T-cell expansions have been
described following viral infections and in elderly humans
[21]. Indeed, it has been reported that initial clonal T-
LGL proliferations might no longer be detectable, after the
development of autoimmunity [19].
Similar notions apply for NK-LGL expansions, although
clonality is diﬃcult to establish in NK-LGL proliferations,
because of the lack of TCR gene rearrangements in NK-LGLs
[22]. However, some of the NK-LGL lymphocytosis have
been shown to be polyclonal [23]. The majority of patients
with T-LGL and NK-LGL proliferations may have lower
LGL expansions that only become apparent if an absolute
lymphocytosis or an increased proportion of peripheral lym-
phocytes with an LGL phenotype is speciﬁcally investigated
[16].
4. Treatment
The major goal in treating PRCA is to induce a remis-
sion with the recovery of erythropoiesis, thereby providing
relief from transfusions and avoiding transfusion-related
complications. The therapeutic strategy usually focuses
on immunosuppressive treatments, until a remission is
obtained. Remissions have been achieved by treatment with
corticosteroids, cyclophosphamide, cyclosporine A (one of
the leading drugs for PRCA treatment, a T-cell targeted
therapy), antithymocyte globulin, splenectomy, and plasma-
pheresis. Recently, the eﬃcacies of the anti-CD20 mono-
clonal antibody, rituximab, and anti-CD52 monoclonal anti-
body, alemtuzumab, have been reported to induce remission
inresistantcasesofPRCA.Othertherapeuticoptionsinclude
intravenous immunoglobulin, thymectomy, or peptide-
based agonists for the erythropoietin receptor (Table 4)
[5].
Immunosuppressive therapy and/or chemotherapy (im-
munosuppressive properties in cases of malignant lym-
phoma) are eﬀective for improving anaemia in the majority
of patients with PRCA, due to lymphoproliferative disorders.
However, in a signiﬁcant portion of patients, remission of
anaemia is maintained, even without immunosuppressive
therapy. These results suggest indeed that durable main-
tenance-free remission of anaemia may be obtained in lym-
phoproliferative disorders-associated PRCA and that PRCA
may occur as paraneoplastic syndrome of lymphoid malig-
nancies [7].
The mechanism of action of rituximab in PRCA is
not entirely clear. The most obvious explanation is the
elimination of antibody producing tumor cells. However, the
rapid and dramatic response even with the persistence of
residualneoplasticcellsinsomepatientsraisesthepossibility
of other mechanisms, as well [11]. Moreover, intravenous
immunoglobulin contains neutralizing antibody againstpar-
vovirus B19 and has been reported to be eﬀective for PRCA
cases associated to parvovirus B19 infection [5].
The anti-CD52 monoclonal antibody alemtuzumab tar-
gets against CD52 antigen, present on B and T lympho-
cytes, NK cells, monocytes/macrophages, dendritic cells, and
eosinophils, but not on human haematopoietic stem cells.
TherationalebehindtheuseofalemtuzumabinPRCAisthat
T lymphocytes are thought to play an important role in the
autoimmune pathogenesis of PRCA, as they are involved in
the control of the expansion of immunoglobulin-producing
autoreactive B-lymphocyte clones [5]. Finally, PRCA due
to autoantibodies against endogenous erythropoietin might
occur, especially to patients previously treated with recom-
binant human erythropoietin. The serum of PRCA patients
with anti-erythropoietin antibody inhibits the growth of
erythroid progenitor cells in vitro. That is why peptide-based
erythropoietinreceptoragonistsfortreatingPRCAhavebeen
developed [5].The Scientiﬁc World Journal 5
Table 3: Proposed molecular mechanisms for PRCA, due to lymphoproliferative disorders [2, 15–17, 19, 20].
Bc e l l s
IgG antibodies, either complement-binding, directly cytotoxic, targeting erythroblasts in vitro or inhibiting haemoglobin synthesis [15].
Antibodies produced following a viral or bacterial infection that might cross-react with erythroid precursor cells or erythropoietin [16].
Anti-erythropoietin antibodies, immune complexes with erythropoietin, which result in functional inactivation [2, 16].
Obstruction of the erythropoietin receptor by anti-erythroblast antibodies [16].
T cells, NK cells
MHC-I-restricted CD8(+) cytotoxic T-lymphocytes [17].
MHC-unrestricted CD3(+) T-LGLs with TCR expressing KIRs [17].
B cells, T cells, NK cells
MHC-unrestricted CD3(−) NK-LGLs without TCR, which may be positively triggered by circulating antibody against red-cell antigens
activating NK-receptors and adhesion molecules [17].
Antibody cross-linking the TCR of the T-LGLs with the Fc receptor on target cells [19, 20].
Antibody cross-linking the Fc receptor on the T-LGLs or NK-LGLs (CD16) with any speciﬁc ligand for the antibody on the target cells
[19, 20].
Table 4: Therapeutic strategies for PRCA [5].
Corticosteroids
Cytotoxic immunosuppressive treatments (cyclophosphamide)
Cyclosporine A
Antithymocyte globulin
Splenectomy
Plasmapheresis
Anti-CD20 monoclonal antibody (rituximab)
Anti-CD52 monoclonal antibody (alemtuzumab)
Intravenous immunoglobulin
Thymectomy
Peptide-based agonists for the erythropoietin receptor
5. Discussion:Additional Comments
It is well established that viral infections, such as parvovirus
B19 [24] or Epstein-Barr Virus (EBV) [8], may cause
PRCA, especially in immunocompromised patients (due
to Human Immunodeﬁciency Virus (HIV) infection, or
after chemotherapy or after transplantation). A case of
chronic parvovirus B19 infection leading to red cell aplasia
followingtreatmentofHodgkinlymphomahasbeenrecently
reported [25]. These patients might be unable to mount
a neutralizing antibody response against the autoimmune
background of PRCA, because of persistent bone marrow
and host immunity insuﬃciency. However, the evaluation
of EBV or parvovirus B19 infection with serological tests in
immunocompromised patients with secondary PRCA, is not
reliable, as antibody production is absent or minimal [24].
From the point of view regarding the pathogenesis of
lymphoproliferative disorder-associated PRCA, it is inter-
esting that positive Coombs test is often associated with
PRCA, which suggests the role of autoreactive antibody in
such cases [7]. However, the diﬀerence between autoim-
mune hemolytic anaemia (AIHA) noted in lymphomas and
lymphoproliferative disorder-induced PRCA, seems to be
the level of maturity of the red-cell line, which receives
the immune attack. In PRCA, an autoreactive antibody
against the erythroid precursors might be responsible for
the disease, whereas in AIHA the autoreactive antibody
targets mature erythroid cells. After an analysis of AIHA or
Evans’ syndrome, encountered in patients with NHL, it has
been reported that warm antibody-mediated AIHA is more
frequentinB-celllymphomas,whilecoldantibody-mediated
AIHA mainly occurs in T-cell lymphomas [26]. Additionally,
in all cases of AITL associated with PRCA, positive Coombs
test has been noted [12]. Coexistence of AIHA and PRCA in
malignant lymphoma has also been reported [8].
In addition, the expansion of LGLs can be easily missed
or underestimated in the analysis of bone marrow histology
of PRCA patients, because it may be rather scanty. In some
patients with documented clonal T-LGL proliferations, the
clonal LGLs account for less than 5% of the bone marrow
cells. It is possible that in some anaemic patients with
increased levels of LGLs, not all erythroblasts are destroyed
by the LGLs and the bone marrow reveals merely reduced
erythropoiesis, but not a true PRCA [16]. Occasionally, clon-
ally expanded lymphocytes with a characteristic CD3(+),
CD57(+) phenotype may not have LGL morphology on a
peripheral smear, but may indeed represent in vivo antigen-
activated cytotoxic eﬀector T cells. Thus, an increase of
CD3(+)/CD56(−) or CD3(−)/CD56(+) cells by peripheral
blood ﬂow cytometry and/or an inverted CD4(+)/CD8(+)
cellratiosuggeststheexistenceofLGLleukaemia[5].Impor-
tantly, a higher percentage of erythroid progenitors (>5%)
does not exclude a diagnosis of PRCA in an appropriate
clinical setting [27].
Averyinterestingaspectoflymphoproliferativedisorder-
associated PRCA is that, while after chemotherapy, the disor-
der might be at remission, PRCA may insist. Thus, while the
number of neoplastic cells in the bone marrow might decline
after chemotherapy, PRCA may continue to be present
[13]. However, the accurate detection of lymphomatic bone
marrow involvement in patients with PRCA is of crucial
importance because of the therapeutic consequences. Bone
marrow trephine biopsy (BMB) is currently regarded as the
method of choice for the evaluation of the bone marrow in6 The Scientiﬁc World Journal
lymphoma, but it is invasive, has a risk of complications, and
lacks suﬃcient sensitivity, due to the possibility of sampling
errors. Bone marrow imaging, if accurate, may partially
replace BMB and may improve the sensitivity of BMB by
guiding the biopsy to the location that appears to be involved
by lymphoma at imaging [28].
The molecular, genetic, and immunologic events impli-
cated in the pathogenesis of lymphoproliferative disorder-
associatedPRCAarecomplexandnotyetfullyelucidated.An
overview on speculating the most important mechanisms,
based on existing literature evidence has been provided.
Moreover, case reports in conjunction with diﬀerent entities
of B- T- NK-cell lymphoproliferative malignancies inducing
PRCA have been described. Further investigation is required
to deﬁne the pathophysiology of PRCA at a molecular level
and to provide convincing evidence why it might emerge as
a rare complication of lymphoproliferative disorders.
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